Trials / Unknown
UnknownNCT05367232
A Study of ICP-033 in Patients With Advanced Solid Tumors
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-033 in Patients With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-033 tablet | Administered orally, once a day, 28 days per cycle |
Timeline
- Start date
- 2022-02-25
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2022-05-10
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05367232. Inclusion in this directory is not an endorsement.